Drug Trial Radar · NCT01986270
Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo
Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,141
Actual
Start
Dec 1996
Primary completion
Jan 1998
Study completion Jan 1998
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 18, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine.
Conditions
- Migraine With or Without Aura
Interventions
PlaceboDrug
Matching Placebo
Eletriptan 40 mgDrug
40mg oral
Eletriptan 80 mgDrug
80mg oral
Sumatriptan 25 mgDrug
25mg oral
Sumatriptan 50 mgDrug
50mg oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Headache response at 1 hour after the first dose for the first attack.Time frame: 1 hour
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.